| 张朝柱,何明霞,王 清,扈玉婕,刘 宁,金立伟.英夫利西单抗联合复合益生菌对炎症性肠病患者肠黏膜屏障、炎症因子、细胞免疫功能及骨代谢指标的影响[J].现代生物医学进展英文版,2021,(20):3954-3958. |
| 英夫利西单抗联合复合益生菌对炎症性肠病患者肠黏膜屏障、炎症因子、细胞免疫功能及骨代谢指标的影响 |
| Effects of Infliximab Combined with Compound Probiotics on Intestinal Mucosal Barrier, Inflammation Factors, Cellular Immune Function and Bone Metabolism Indicators in Patients with Inflammatory Bowel Disease |
| Received:April 06, 2021 Revised:April 28, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.20.031 |
| 中文关键词: 英夫利西单抗 复合益生菌 炎症性肠病 肠黏膜屏障 炎症因子 免疫功能 骨代谢 |
| 英文关键词: Infliximab Compound probiotics Inflammatory bowel disease Intestinal mucosal barrier Inflammation factors Immune function Bone metabolism |
| 基金项目:全军保健专项科研基金项目（18BJZ125） |
|
| Hits: 941 |
| Download times: 408 |
| 中文摘要: |
| 摘要 目的：探讨英夫利西单抗联合复合益生菌对炎症性肠病（IBD）患者肠黏膜屏障、细胞免疫功能及骨代谢指标的影响。方法：研究对象选取2017年3月~2019年12月期间来我院诊治的290例IBD患者，信封抽签法分为对照组和研究组，各145例。研究组采用英夫利西单抗联合复合益生菌治疗，对照组采用英夫利西单抗治疗，比较两组患者疗效、肠黏膜屏障功能、T细胞亚群、骨代谢指标及炎症因子水平，并记录两组治疗期间不良反应情况。结果：对照组治疗2疗程后的临床总有效率为71.72%（104/145），低于研究组的86.21%（125/145）（P<0.05）。治疗1疗程后、治疗2疗程后，两组患者的C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、骨钙素（BGP）、Ｉ-型胶原Ｃ末端肽（CTX）、CD8+及尿乳果糖/甘露醇比值均较治疗前降低，治疗2疗程后上述指标水平低于治疗1疗程后，且研究组低于对照组（P<0.05）。治疗1疗程后、治疗2疗程后，两组的CD4+、CD4+/ CD8+较治疗前升高，治疗2疗程后上述指标水平高于治疗1疗程后，且研究组高于对照组（P<0.05）。两组不良反应发生率对比无统计学差异（P>0.05）。结论：英夫利西单抗联合复合益生菌治疗IBD患者，可减轻患者的炎症反应，提高患者的免疫功能，改善其肠黏膜屏障和骨代谢指标，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of infliximab combined with compound probiotics on intestinal mucosal barrier, inflammation factors, cellular immune function and bone metabolism indicators in patients with inflammatory bowel disease (IBD). Methods: Participants 290 patients with IBD who came to our hospital from March 2017 to December 2019 were selected, they were randomly divided into control group and study group, 145 cases in each group. The study group was treated with infliximab combined with compound probiotics, and the control group was treated with infliximab, the efficacy, intestinal mucosal barrier function, T cell subsets, bone metabolism indicators and inflammation factors levels of the two groups were compared. The adverse reactions of the two groups during the treatment were recorded. Results: The total effective rate of the control group was 71.72% (104/145), which was Lower than 86.21% (125/145) of the study group (P<0.05). The levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), osteocalcin (BGP), Ｉ-type collagen C-terminal peptide (CTX) and CD8+, as well as the urinary lactulose / mannitol ratio in the two groups at 1 course after treatment and 2 course after treatment were all lower than those before treatment. 10 weeks after treatment, the above indicators were lower than those at 1 course after treatment, and the study group was lower than the control group(P<0.05). CD4+ and CD4+/CD8+ in the two groups at 1 course after treatment and 2 course after treatment were higher than those before treatment. CD4+ and CD4+/CD8+ levels at 2 course after treatment were higher than that at 1 course after treatment, and the study group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Infliximab combined with probiotics in the treatment of IBD patients can reduce the inflammatory reaction, improve the immune function, improve the intestinal mucosal barrier and bone metabolism index, and has good safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
